Catalyst Pharmaceuticals, Inc. files DEF 14A Proxy Statement

TL;DR

<b>Catalyst Pharmaceuticals, Inc. has filed its DEF 14A proxy statement detailing corporate governance and executive compensation information.</b>

AI Summary

CATALYST PHARMACEUTICALS, INC. (CPRX) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Catalyst Pharmaceuticals, Inc. filed a DEF 14A proxy statement on April 10, 2024. The filing covers the period ending May 21, 2024. The company's principal executive offices are located at 355 Alhambra Circle, Suite 801, Coral Gables, FL 33134. Catalyst Pharmaceuticals, Inc. was formerly known as Catalyst Pharmaceutical Partners, Inc. The SIC code for the company is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking CATALYST PHARMACEUTICALS, INC., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions. The DEF 14A provides insights into the company's financial performance and strategic direction through its disclosures.

Risk Assessment

Risk Level: low — CATALYST PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance procedures rather than immediate material events.

Analyst Insight

Shareholders should review the executive compensation details and any proposed resolutions in the proxy statement before the annual meeting.

Key Numbers

• 2024-04-10 — Filing Date (DEF 14A filing date)
• 2024-05-21 — Period of Report (Conformed period of report for DEF 14A)
• 1231 — Fiscal Year End (Company's fiscal year end)
• 2834 — SIC Code (Standard Industrial Classification code)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — Filer name
• CPRX (company) — Ticker symbol
• DEF 14A (document) — Filing type
• 2024-04-10 (date) — Filing date
• 2024-05-21 (date) — Period of report
• 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL 33134 (address) — Business address
• 2834 (industry_code) — Standard Industrial Classification
• Catalyst Pharmaceutical Partners, Inc. (company) — Former company name

FAQ

Industry Context

Catalyst Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies for rare diseases.

Regulatory Implications

The DEF 14A filing is a standard requirement under the Securities Exchange Act of 1934 for public companies to provide information to shareholders regarding annual meetings and related matters.

What Investors Should Do

1. Review the executive compensation tables and related disclosures.
2. Understand the proposals to be voted on at the upcoming shareholder meeting.
3. Note any changes in corporate governance practices outlined in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies and does not represent a change from previous filings of the same type.

Key Financial Figures

• $0.001 — f shares of our common stock, par value $0.001 per share (the " Common Stock "), as of

Filing Documents

• d762054ddef14a.htm (DEF 14A) — 683KB
• g762054g02g02.jpg (GRAPHIC) — 39KB
• g762054g03g03.jpg (GRAPHIC) — 19KB
• g762054g44g44.jpg (GRAPHIC) — 96KB
• g762054g45g01.jpg (GRAPHIC) — 89KB
• g762054g45g02.jpg (GRAPHIC) — 94KB
• 0001193125-24-091926.txt (&nbsp;) — 2118KB
• cprx-20231231.xsd (EX-101.SCH) — 4KB
• cprx-20231231_def.xml (EX-101.DEF) — 3KB
• cprx-20231231_lab.xml (EX-101.LAB) — 4KB
• cprx-20231231_pre.xml (EX-101.PRE) — 2KB
• d762054ddef14a_htm.xml (XML) — 147KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 45 Certain Relationships and Related Party Transactions 48 Other Matters 48 Contacting the Board of Directors 48 Stockholder Proposals 49 Additional Information 49 Annex A – Amendment No. 4 to Catalyst Pharmaceuticals, Inc. 2018 Stock Incentive Plan 50 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON TUESDAY, MAY 21, 2024 INFORMATION REGARDING SOLICITATION AND VOTING This Proxy Statement contains information about our 2024 Annual Meeting of Stockholders (the " Annual Meeting "). The Annual Meeting will be held on Tuesday, May 21, 2024, beginning at 9:00 a.m., Eastern Time. Holders of record of shares of our common stock, par value $0.001 per share (the " Common Stock "), as of the close of business on Thursday, March 28, 2024 (the " Record Date "), will be entitled to notice of and to vote at the Annual Meeting and any continuation, postponement or adjournment thereof. As of the Record Date, there were 118,011,092 shares of our Common Stock outstanding and entitled to notice of and to vote at the Annual Meeting. Each share of Common Stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting. The Annual Meeting will be a virtual meeting held via the internet. In order to attend the Annual Meeting online, you must register in the manner set forth below under "How do I virtually attend the annual meeting?". Upon completing your registration, you will receive further instructions via e-mail, including your unique links that will allow you access to the meeting. Please be sure to follow instructions found on your proxy card and subsequent instructions that will be delivered to you via e-mail. There will not be a physical meeting location, and stockholders will not be able to attend the annual meeting of stockholders in person. Except where the context otherwise requires, references to "Catalyst Pharmaceuticals", "C

View Full Filing

View this DEF 14A filing on SEC EDGAR